BenÃ-cio N Frey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1565641/publications.pdf

Version: 2024-02-01

271 papers

11,588 citations

51 h-index 97 g-index

280 all docs

280 docs citations

times ranked

280

11537 citing authors

#	Article	IF	CITATIONS
1	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. Cerebellum, 2023, 22, 26-36.	2.5	o
2	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.5	0
3	A pilot study examining the effectiveness of a short-term, DBT informed, skills group for emotion dysregulation during the perinatal period Psychological Services, 2023, 20, 697-707.	1.5	3
4	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5
5	Validation and psychometric properties of the Spanish Mood Rhythm Instrument. Biological Rhythm Research, 2022, 53, 841-853.	0.9	4
6	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16ÂWeeks of Pharmacotherapy: A CAN-BIND Report. Cerebral Cortex, 2022, 32, 1223-1243.	2.9	6
7	Brain age in mood and psychotic disorders: a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2022, 145, 42-55.	4.5	32
8	Lifestyle predictors of depression and anxiety during COVID-19: a machine learning approach. Trends in Psychiatry and Psychotherapy, 2022, , .	0.8	2
9	Investigating the relationship between objective measures of sleep and self-report sleep quality in healthy adults: a review. Journal of Clinical Sleep Medicine, 2022, 18, 927-936.	2.6	32
10	Melatonin use during pregnancy and lactation: A scoping review of human studies. Revista Brasileira De Psiquiatria, 2022, 44, 342-348.	1.7	15
11	Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multiâ€disciplinary literature review and agenda for future research from the ISBD task force on chronobiology. Bipolar Disorders, 2022, 24, 232-263.	1.9	36
12	Functional and cognitive impairment in the first episode of depression: A systematic review. Acta Psychiatrica Scandinavica, 2022, 145, 156-185.	4.5	42
13	"One Degree of Separation― A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. Canadian Journal of Psychiatry, 2022, , 070674372110706.	1.9	6
14	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. Journal of Affective Disorders, 2022, 300, 50-58.	4.1	3
15	Longitudinal Changes in Sleep, Biological Rhythms, and Light Exposure From Late Pregnancy to Postpartum and Their Impact on Peripartum Mood and Anxiety. Journal of Clinical Psychiatry, 2022, 83,	2.2	6
16	Adaptation and validation of the Mood Rhythm Instrument for use in Brazilian adolescents. Revista Brasileira De Psiquiatria, 2022, 44, 264-270.	1.7	1
17	Physician suicide demographics and the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2022, 44, 124-135.	1.7	5
18	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	2.6	3

#	Article	IF	CITATIONS
19	Network properties of intracortical myelin associated with psychosocial functioning in bipolar I disorder. Bipolar Disorders, 2022, , .	1.9	1
20	Investigating biological rhythms disruptions across the menstrual cycle in women with comorbid bipolar disorder and premenstrual dysphoric disorder. Archives of Women's Mental Health, 2022, 25, 345-353.	2.6	2
21	The prevalence of borderline personality features and borderline personality disorder during the perinatal period: a systematic review and meta-analysis. Archives of Women's Mental Health, 2022, 25, 277-289.	2.6	9
22	Biophysical compartment models for single-shell diffusion MRI in the human brain: a model fitting comparison. Physics in Medicine and Biology, 2022, 67, 055009.	3.0	1
23	Intolerance of Uncertainty and Perfectionistic Beliefs About Parenting as Cognitive Mechanisms of Symptom Change During Cognitive Behavior Therapy for Perinatal Anxiety. Behavior Therapy, 2022, 53, 738-750.	2.4	3
24	Conversion to major neurocognitive disorder after COVIDâ€19 in a woman with bipolar disorder: A 6â€year longitudinal case report. Bipolar Disorders, 2022, 24, 451-456.	1.9	1
25	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior, 2022, 12, e2555.	2.2	3
26	Effective recommendations towards healthy routines to preserve mental health during the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2022, 44, 136-146.	1.7	5
27	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry, 2022, 12, 101.	4.8	17
28	A DSM-5-based tool to monitor concurrent mood and premenstrual symptoms: the McMaster Premenstrual and Mood Symptom Scale (MAC-PMSS). BMC Women's Health, 2022, 22, 96.	2.0	1
29	The relationship between parental bonding and mood, anxiety and related disorders in adulthood: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 307, 221-236.	4.1	14
30	Evaluation of an Augmented Cognitive Behavioural Group Therapy for Perinatal Generalized Anxiety Disorder (GAD) during the COVID-19 Pandemic. Journal of Clinical Medicine, 2022, 11, 209.	2.4	6
31	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. Psychiatry Research, 2022, 312, 114557.	3.3	1
32	P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242.	1.3	1
33	An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. BMC Psychiatry, 2022, 22, 303.	2.6	10
34	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613.	4.0	1
35	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370.	1.7	0
36	Investigation of blood-brain barrier disruption in an animal model of mania induced by D-amphetamine. Journal of Affective Disorders Reports, 2022, 9, 100368.	1.7	1

#	Article	IF	Citations
37	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.7	9
38	Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120.	2.7	8
39	Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14.	4.1	0
40	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194.	4.8	11
41	Novel mechanism of action for the mood stabilizer lithium. Bipolar Disorders, 2021, 23, 76-83.	1.9	10
42	Cognitive Behavior Therapy for Women With Generalized Anxiety Disorder in the Perinatal Period: Impact on Problematic Behaviors. Behavior Therapy, 2021, 52, 907-916.	2.4	7
43	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) ConceL'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.	ermant	54
44	The Revised Mood Rhythm Instrument: A Large Multicultural Psychometric Study. Journal of Clinical Medicine, 2021, 10, 388.	2.4	2
45	Intracortical myelination. , 2021, , 417-426.		0
46	Predicting Brain Age at Slice Level: Convolutional Neural Networks and Consequences for Interpretability. Frontiers in Psychiatry, 2021, 12, 598518.	2.6	10
47	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	4.8	22
48	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. Frontiers in Psychiatry, 2021, 12, 617997.	2.6	32
49	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs, 2021, 35, 291-304.	5.9	4
50	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. Pharmacopsychiatry, 2021, 54, 225-231.	3.3	1
51	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs, 2021, 35, 439-450.	5.9	4
52	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CANâ€BIND 1 report. Personality and Mental Health, 2021, 15, 273-282.	1.2	1
53	Depression in midlife women attending a menopause clinic is associated with a history of childhood maltreatment. Climacteric, $2021, 1.5$.	2.4	2
54	Identifying Nonlinear Patterns of 5-Year Suicide Risk Incidence in Youth: A Gradient Tree Boosting and SHAP Study. Biological Psychiatry, 2021, 89, S283.	1.3	1

#	Article	IF	CITATIONS
55	Daily Variability in Affective, Somatic, and Cognitive Symptoms Against Validated Scores of Anxiety and Depression: A Prospective Preliminary Study. Biological Psychiatry, 2021, 89, S111.	1.3	O
56	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. Psychiatry Research - Neuroimaging, 2021, 312, 111289.	1.8	4
57	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS ONE, 2021, 16, e0253023.	2.5	4
58	Cognitive complaints in individuals recently diagnosed with bipolar disorder: A cross-sectional study. Psychiatry Research, 2021, 300, 113894.	3.3	4
59	Preliminary insights into the genetic architecture of postpartum depressive symptom severity using polygenic risk scores. Personalized Medicine in Psychiatry, 2021, 27-28, 100081.	0.1	2
60	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. Communications Biology, 2021, 4, 903.	4.4	16
61	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
62	Exploring brain connectivity changes in major depressive disorder using <scp>functionalâ€structural</scp> data fusion: A CANâ€BINDâ€1 study. Human Brain Mapping, 2021, 42, 4940-4957.	3.6	8
63	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	4.8	3
64	Comorbid Premenstrual Dysphoric Disorder and Bipolar Disorder: A Review. Frontiers in Psychiatry, 2021, 12, 719241.	2.6	15
65	Sleep, biological rhythms and anxiety in the perinatal period: a systematic review protocol. BMJ Open, 2021, 11, e046767.	1.9	0
66	Suicidal Risk in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Systematic Review and Meta-Analysis. Journal of Women's Health, 2021, 30, 1693-1707.	3.3	24
67	Risk factors for new-onset bipolar disorder in a community cohort: A five-year follow up study. Psychiatry Research, 2021, 303, 114109.	3.3	4
68	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. Translational Psychiatry, 2021, 11, 469.	4.8	1
69	The role of emotion dysregulation in cognitive behavioural group therapy for perinatal anxiety: Results from a randomized controlled trial and routine clinical care. Journal of Affective Disorders, 2021, 292, 517-525.	4.1	4
70	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	2.7	8
71	5-year incidence of suicide-risk in youth: A gradient tree boosting and SHAP study. Journal of Affective Disorders, 2021, 295, 1049-1056.	4.1	11
72	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. Journal of Affective Disorders, 2021, 295, 1095-1101.	4.1	7

#	Article	IF	CITATIONS
73	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. Neurolmage: Clinical, 2021, 32, 102864.	2.7	13
74	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	4. 5	38
75	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
76	The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study. Journal of Medical Internet Research, 2021, 23, e25730.	4.3	8
77	Cognition and its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble DA®pressif Majeur: Une A‰tude Can-Bind-1. Canadian	1.9	0
78	Characterizing worry content and impact in pregnant and postpartum women with anxiety disorders during COVIDâ€19. Clinical Psychology and Psychotherapy, 2021, , .	2.7	3
79	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. Frontiers in Neuroinformatics, 2021, 15, 622951.	2.5	2
80	Validation of the intolerance of uncertainty scale as a screening tool for perinatal anxiety. BMC Pregnancy and Childbirth, 2021, 21, 829.	2.4	7
81	Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Probable Alzheimer Patients. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, .	1.3	2
82	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	4.5	17
83	The Link between Estradiol and Neuroplasticity in Transgender Women after Gender-Affirming Surgery: A Bimodal Hypothesis. Neuroendocrinology, 2020, 110, 489-500.	2.5	4
84	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	5.4	37
85	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	5 . 9	49
86	Preeclampsia as a risk factor for postpartum depression and psychosis: a systematic review and meta-analysis. Archives of Women's Mental Health, 2020, 23, 493-505.	2.6	62
87	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. International Journal of Neuropsychopharmacology, 2020, 23, 88-95.	2.1	12
88	Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. Australian and New Zealand Journal of Psychiatry, 2020, 54, 393-401.	2.3	27
89	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. Journal of Affective Disorders, 2020, 264, 414-424.	4.1	6
90	Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104502.	1.6	9

#	Article	IF	Citations
91	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	4.1	4
92	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. Human Brain Mapping, 2020, 41, 1400-1415.	3.6	7
93	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. Biological Psychiatry, 2020, 87, S431.	1.3	1
94	Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 197-213.	1.7	9
95	Neural correlates of verbal recognition memory in obese adults with and without major depressive disorder. Brain and Behavior, 2020, 10, e01848.	2.2	5
96	Quality assurance assessment of a specialized perinatal mental health clinic. BMC Pregnancy and Childbirth, 2020, 20, 485.	2.4	10
97	The Early Burden of Disability in Individuals With Mood and Other Common Mental Disorders in Ontario, Canada. JAMA Network Open, 2020, 3, e2020213.	5.9	27
98	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	5.4	23
99	Measuring circadian function in bipolar disorders: Empirical and conceptual review of physiological, actigraphic, and selfâ€report approaches. Bipolar Disorders, 2020, 22, 693-710.	1.9	49
100	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	4.1	18
101	Emotional reactivity and explicit emotional memory biases in major depressive disorder during euthymia. Psychiatry Research, 2020, 285, 112847.	3.3	1
102	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. Neurolmage: Clinical, 2020, 25, 102178.	2.7	10
103	Cognitive behavioral therapy for perinatal anxiety: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 423-432.	2.3	32
104	Validation of the English version of the Mood Rhythm Instrument. BMC Psychology, 2020, 8, 35.	2.1	6
105	Objective and subjective vasomotor symptom outcomes in the CBT-Meno randomized controlled trial. Climacteric, 2020, 23, 482-488.	2.4	4
106	Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: A prospective study. Psychiatry and Clinical Neurosciences, 2020, 74, 418-423.	1.8	9
107	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	9
108	Bipolar Disorder in Women: Menstrual Cycle, Perinatal Period, and Menopause Transition., 2020,, 59-71.		3

#	Article	IF	Citations
109	Understanding the complex interplay between violence, depression and suicidal ideation in women: Time for a comprehensive sex- and gender-based approach. Revista Brasileira De Psiquiatria, 2020, 42, 467-468.	1.7	1
110	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. Innovations in Clinical Neuroscience, 2020, 17, 30-40.	0.1	6
111	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	4.8	113
112	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. Journal of Affective Disorders, 2019, 257, 765-773.	4.1	20
113	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	4.8	33
114	Effects of Estradiol Therapy on Resting-State Functional Connectivity of Transgender Women After Gender-Affirming Related Gonadectomy. Frontiers in Neuroscience, 2019, 13, 817.	2.8	8
115	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 913-924.	1.5	21
116	T97. Predicting Functioning and Quality of Life Using Objective and Subjective Measures of Sleep and Biological Rhythms in Major Depressive and Bipolar Disorder. Biological Psychiatry, 2019, 85, S166.	1.3	0
117	Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. Alcoholism: Clinical and Experimental Research, 2019, 43, 550-563.	2.4	56
118	Effort-based decision-making is affected by overweight/obesity in major depressive disorder. Journal of Affective Disorders, 2019, 256, 221-227.	4.1	16
119	Explicit emotional memory biases in mood disorders: A systematic review. Psychiatry Research, 2019, 278, 162-172.	3.3	12
120	Impact of a structured, group-based running programme on clinical, cognitive and social function in youth and adults with complex mood disorders: a 12-week pilot study. BMJ Open Sport and Exercise Medicine, 2019, 5, e000521.	2.9	2
121	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. Neurolmage, 2019, 197, 589-597.	4.2	24
122	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S254.	1.3	0
123	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. Biological Psychiatry, 2019, 85, S344-S345.	1.3	0
124	Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 2019, 33, 502-510.	4.0	12
125	Biological and psychosocial predictors of anxiety worsening in the postpartum period: A longitudinal study. Journal of Affective Disorders, 2019, 250, 218-225.	4.1	29
126	Altered hippocampal function with preserved cognitive performance in treatment-naive major depressive disorder. NeuroReport, 2019, 30, 46-52.	1.2	3

#	Article	IF	Citations
127	Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 683-696.	2.3	48
128	Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder. NeuroReport, 2019, 30, 378-382.	1.2	3
129	Cognitive behavior therapy for menopausal symptoms (CBT-Meno). Menopause, 2019, 26, 972-980.	2.0	37
130	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	4.5	22
131	From anatomy to function: the role of the somatosensory cortex in emotional regulation. Revista Brasileira De Psiquiatria, 2019, 41, 261-269.	1.7	184
132	The use of cannabinoids for sleep: A critical review on clinical trials Experimental and Clinical Psychopharmacology, 2019, 27, 383-401.	1.8	79
133	Age-related deficits in intracortical myelination in young adults with bipolar disorder type I. Journal of Psychiatry and Neuroscience, 2019, 44, 79-88.	2.4	14
134	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	2.4	37
135	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	61
136	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	2.2	16
137	Non-pharmacological interventions for improving postpartum maternal sleep: A systematic review and meta-analysis. Sleep Medicine Reviews, 2018, 41, 87-100.	8.5	35
138	Structural and functional changes in the somatosensory cortex in euthymic females with bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1075-1083.	2.3	48
139	Association of intracortical myelin and cognitive function in bipolar I disorder. Acta Psychiatrica Scandinavica, 2018, 138, 62-72.	4.5	13
140	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
141	A longitudinal study of neurotrophic, oxidative, and inflammatory markers in first-onset depression in midlife women. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 771-781.	3.2	32
142	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	4.1	59
143	Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. Journal of Affective Disorders, 2018, 225, 54-63.	4.1	31
144	Volumetric MRI Analysis of a Case of Severe Ventriculomegaly. Frontiers in Human Neuroscience, 2018, 12, 495.	2.0	4

#	Article	IF	CITATIONS
145	Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. Journal of Psychiatry and Neuroscience, 2018, 43, 298-316.	2.4	106
146	The Menopause Visual Analogue Scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition. Climacteric, 2018, 21, 502-508.	2.4	4
147	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
148	Prospective Assessment of Daily Patterns of Mood-Related Symptoms. Frontiers in Psychiatry, 2018, 9, 370.	2.6	7
149	Effects of a 12-week running programme in youth and adults with complex mood disorders. BMJ Open Sport and Exercise Medicine, 2018, 4, e000314.	2.9	20
150	Risk factors of new onset anxiety and anxiety exacerbation in the perinatal period: A systematic review and meta-analysis. Journal of Affective Disorders, 2018, 238, 626-635.	4.1	63
151	Rhythmicity of Mood Symptoms in Individuals at Risk for Psychiatric Disorders. Scientific Reports, 2018, 8, 11402.	3.3	19
152	The Role of Circadian Rhythms in Postpartum Sleep and Mood. Sleep Medicine Clinics, 2018, 13, 359-374.	2.6	26
153	Subtle persistent working memory and selective attention deficits in women with premenstrual syndrome. Psychiatry Research, 2017, 249, 354-362.	3.3	19
154	Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Scientific Reports, 2017, 7, 41382.	3.3	19
155	Resting state functional connectivity in women with bipolar disorder during clinical remission. Bipolar Disorders, 2017, 19, 97-106.	1.9	43
156	Influence of endogenous estradiol, progesterone, allopregnanolone, and dehydroepiandrosterone sulfate on brain resting state functional connectivity across the menstrual cycle. Fertility and Sterility, 2017, 107, 1246-1255.e4.	1.0	47
157	Ageâ€related mapping of intracortical myelin from late adolescence to middle adulthood using T ₁ â€weighted MRI. Human Brain Mapping, 2017, 38, 3691-3703.	3.6	35
158	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	12.8	144
159	Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder. Expert Review of Molecular Diagnostics, 2017, 17, 107-108.	3.1	12
160	A statistical method to calculate blood contamination in the measurement of salivary hormones in healthy women. Clinical Biochemistry, 2017, 50, 436-439.	1.9	8
161	Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Archives of Women's Mental Health, 2017, 20, 713-719.	2.6	35
162	Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEPâ€BD study. Acta Psychiatrica Scandinavica, 2017, 136, 473-482.	4.5	33

#	Article	IF	CITATIONS
163	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Scientific Reports, 2017, 7, 7473.	3.3	28
164	Altered intracortical myelin staining in the dorsolateral prefrontal cortex in severe mental illness. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 369-376.	3.2	37
165	Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life. Revista Brasileira De Psiquiatria, 2017, 39, 140-146.	1.7	30
166	Salivary cortisol during memory encoding in pregnancy predicts postpartum depressive symptoms: a longitudinal study. Trends in Psychiatry and Psychotherapy, 2017, 39, 280-284.	0.8	4
167	The impact of obesity on neuropsychological functioning in adults with and without major depressive disorder. PLoS ONE, 2017, 12, e0176898.	2.5	26
168	Brain Structure and Function in Women with Comorbid Bipolar and Premenstrual Dysphoric Disorder. Frontiers in Psychiatry, 2017, 8, 301.	2.6	23
169	The Mood Rhythm Instrument: development and preliminary report. Revista Brasileira De Psiquiatria, 2016, 38, 148-153.	1.7	11
170	Treating comorbid premenstrual dysphoric disorder in women with bipolar disorder. Journal of Psychiatry and Neuroscience, 2016, 41, E22-E23.	2.4	15
171	Relationship between inflammatory biomarkers and depressive symptoms during late pregnancy and the early postpartum period: a longitudinal study. Revista Brasileira De Psiquiatria, 2016, 38, 190-196.	1.7	48
172	The association between biological rhythms, depression, and functioning in bipolar disorder: a large multiâ€enter study. Acta Psychiatrica Scandinavica, 2016, 133, 102-108.	4.5	66
173	Effect of obesity on cognition in adults with and without a mood disorder: study design and methods. BMJ Open, 2016, 6, e009347.	1.9	20
174	Sleep, daily activity rhythms and postpartum mood: A longitudinal study across the perinatal period. Chronobiology International, 2016, 33, 791-801.	2.0	21
175	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	1.9	165
176	<scp>RNA</scp> â€sequencing profiles hippocampal gene expression in a validated model of cancerâ€induced depression. Genes, Brain and Behavior, 2016, 15, 711-721.	2.2	10
177	Update on bipolar disorder biomarker candidates. Expert Review of Molecular Diagnostics, 2016, 16, 1209-1220.	3.1	38
178	Biological rhythms, metabolic syndrome and current depressive episode in a community sample. Psychoneuroendocrinology, 2016, 72, 34-39.	2.7	17
179	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	2.6	114
180	Biological rhythms are independently associated with quality of life in bipolar disorder. International Journal of Bipolar Disorders, 2016, 4, 9.	2.2	19

#	Article	IF	Citations
181	Mild Depressive Symptoms During the Third Trimester of Pregnancy Are Associated with Disruptions in Daily Rhythms but Not Subjective Sleep Quality. Journal of Women's Health, 2016, 25, 594-598.	3.3	12
182	Oncodynamic Effect of Cancer on Depression. , 2016, , 105-127.		0
183	Do changes in subjective sleep and biological rhythms predict worsening in postpartum depressive symptoms? A prospective study across the perinatal period. Archives of Women's Mental Health, 2016, 19, 591-598.	2.6	31
184	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. Innovations in Clinical Neuroscience, 2016, 13, 20-31.	0.1	11
185	Assessing intracortical myelin in the living human brain using myelinated cortical thickness. Frontiers in Neuroscience, 2015, 9, 396.	2.8	52
186	Translational Research in Bipolar Disorders. Neural Plasticity, 2015, 2015, 1-3.	2.2	2
187	Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?. Neural Plasticity, 2015, 2015, 1-12.	2.2	139
188	Emotional memory in pregnant women at risk for postpartum depression. Psychiatry Research, 2015, 229, 777-783.	3.3	10
189	Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. Behavioural Brain Research, 2015, 294, 25-35.	2.2	29
190	Cognitive-behavioral group treatment for perinatal anxiety: a pilot study. Archives of Women's Mental Health, 2015, 18, 631-638.	2.6	60
191	Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord. PLoS ONE, 2015, 10, e0142598.	2.5	17
192	Alterations in circadian rhythms are associated with increased lipid peroxidation in females with bipolar disorder. International Journal of Neuropsychopharmacology, 2014, 17, 715-722.	2.1	29
193	Sex hormones and biomarkers of neuroprotection and neurodegeneration: implications for female reproductive events in bipolar disorder. Bipolar Disorders, 2014, 16, 48-57.	1.9	50
194	Val66Met polymorphism and serum brainâ€derived neurotrophic factor in bipolar disorder: an openâ€label trial. Acta Psychiatrica Scandinavica, 2014, 129, 393-400.	4.5	23
195	Comparative Efficacy of the Generalized Anxiety Disorder 7-Item Scale and the Edinburgh Postnatal Depression Scale as Screening Tools for Generalized Anxiety Disorder in Pregnancy and the Postpartum Period. Canadian Journal of Psychiatry, 2014, 59, 434-440.	1.9	126
196	Changes in cortical thickness across the lifespan in major depressive disorder. Psychiatry Research - Neuroimaging, 2013, 214, 204-211.	1.8	59
197	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	2.3	193
198	Comorbid bipolar disorder and premenstrual dysphoric disorder: real patients, unanswered questions. Archives of Women's Mental Health, 2013, 16, 79-81.	2.6	19

#	Article	IF	Citations
199	Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder. Archives of Women's Mental Health, 2013, 16, 83-85.	2.6	13
200	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
201	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.9	14
202	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.9	1
203	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.2	119
204	A primary care-based treatment programme improves postpartum depression at 12â€months. Evidence-Based Mental Health, 2013, 16, 6-6.	4.5	2
205	Soft Bipolar Spectrum and Staging in Bipolar Disorder. Current Psychiatry Reviews, 2013, 9, 33-40.	0.9	0
206	New-onset psychosis following androgen deprivation therapy for prostate cancer. Canadian Journal of Urology, 2013, 20, 6868-70.	0.0	2
207	Depression During the Menopausal Transition: An Update on Epidemiology and Biological Treatments. Focus (American Psychiatric Publishing), 2012, 10, 22-27.	0.8	3
208	Increased cerebral oxidative damage and decreased antioxidant defenses in ovariectomized and sham-operated rats supplemented with vitamin A. Cell Biology and Toxicology, 2012, 28, 317-330.	5.3	26
209	Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-13.	4.0	147
210	Sensitivity and Specificity of the Mood Disorder Questionnaire as a Screening Tool for Bipolar Disorder During Pregnancy and the Postpartum Period. Journal of Clinical Psychiatry, 2012, 73, 1456-1461.	2.2	46
211	Mitochondrial Dysfunction in Bipolar Disorder: Lessons from Brain Imaging and Molecular Markers. Revista Colombiana De PsiquiatrÃa, 2011, 40, 166S-182S.	0.3	6
212	Non-Hormonal Treatment Strategies for Vasomotor Symptoms. Drugs, 2011, 71, 287-304.	10.9	52
213	Depression in Women. Journal of Clinical Psychiatry, 2011, 72, e1563-e1569.	2.2	114
214	Sleep and Circadian Rhythm Disturbances in Bipolar Disorder. Journal of Clinical Psychiatry, 2011, 72, 724.	2.2	9
215	Shift in the brain network of emotional regulation in midlife women. Menopause, 2010, 17, 840-845.	2.0	18
216	The rapid effects of estrogen: a mini-review. Behavioural Pharmacology, 2010, 21, 465-472.	1.7	45

#	Article	IF	Citations
217	A Pilot, 8-Week, Placebo Lead-In Trial of Quetiapine Extended Release for Depression in Midlife Women. Journal of Clinical Psychopharmacology, 2010, 30, 612-615.	1.4	23
218	Gender differences in α-[11C]MTrp brain trapping, an index of serotonin synthesis, in medication-free individuals with major depressive disorder: A positron emission tomography study. Psychiatry Research - Neuroimaging, 2010, 183, 157-166.	1.8	40
219	Plasma Brain-Derived-Neurotrophic Factor levels and cognitive function in euthymic bipolar type I patients. Annals of General Psychiatry, 2010, 9, .	2.7	O
220	Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond. Psychiatric Clinics of North America, 2010, 33, 295-308.	1.3	33
221	Approach to Premenstrual Dysphoria for the Mental Health Practitioner. Psychiatric Clinics of North America, 2010, 33, 257-272.	1.3	17
222	Is there a role for estrogen in treating depression during menopause?. Journal of Psychiatry and Neuroscience, 2010, 35, E6-E7.	2.4	6
223	Quality of Life in Bipolar Disorder. , 2010, , 3591-3606.		1
224	Managing Depression and Anxiety during the Menopausal Transition and Beyond: The Window of Vulnerability. Key Issues in Mental Health, 2009, , 102-114.	0.6	2
225	Electrophysiological correlates of sleep disturbance induced by acute and chronic administration of d-amphetamine. Brain Research, 2009, 1249, 162-172.	2.2	11
226	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, 2009, 114, 1-13.	4.1	75
227	Brainâ€derived neurotrophic factor in bipolar disorder: beyond <i>trait</i> and <i>state</i> : comment on †Decreased levels of serum brainâ€derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders'. Bipolar Disorders, 2009, 11, 221-222.	1.9	11
228	Cognitive function and serum levels of brainâ€derived neurotrophic factor in patients with bipolar disorder. Bipolar Disorders, 2009, 11, 663-671.	1.9	80
229	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. Psiquiatria Biologica, 2009, 16, 60-69.	0.1	0
230	Clinical implications of a staging model for bipolar disorders. Expert Review of Neurotherapeutics, 2009, 9, 957-966.	2.8	214
231	Neuronal Correlates of Brain-derived Neurotrophic Factor Val66Met Polymorphism and Morphometric Abnormalities in Bipolar Disorder. Neuropsychopharmacology, 2009, 34, 1904-1913.	5.4	109
232	Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 300-304.	3.2	109
233	Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a doubleâ€blind, randomized, placeboâ€controlled study. Human Psychopharmacology, 2008, 23, 87-94.	1.5	255
234	Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews, 2008, 32, 675-692.	6.1	416

#	Article	IF	Citations
235	Corrected values of brain metabolites for the article: â€~Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medicationâ€free individuals with bipolar disorder: an <i>in vivo</i> ¹ H MRS study'. Bipolar Disorders, 2008, 10, 849-849.	1.9	5
236	Insight, quality of life and cognitive functioning in euthymic patients with bipolar disorder. Journal of Affective Disorders, 2008, 110, 75-83.	4.1	82
237	Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2008, 111, 135-144.	4.1	442
238	Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. Journal of Psychiatric Research, 2008, 42, 416-421.	3.1	51
239	Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Review of Neurotherapeutics, 2008, 8, 1101-1113.	2.8	146
240	Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: A combined α-[11C]MT and [18F]MPPF positron emission tomography study. NeuroImage, 2008, 42, 850-857.	4.2	27
241	Illness duration and total brain gray matter in bipolar disorder: Evidence for neurodegeneration?. European Neuropsychopharmacology, 2008, 18, 717-722.	0.7	62
242	Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause International, 2008, 14, 123-128.	1.6	79
243	Three-Dimensional Mapping of Hippocampal Anatomy in Unmedicated and Lithium-Treated Patients with Bipolar Disorder. Neuropsychopharmacology, 2008, 33, 1229-1238.	5.4	148
244	Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Revista Brasileira De Psiquiatria, 2008, 30, 243-245.	1.7	129
245	Effects of mood stabilizers on DNA damage in an animal model of mania. Journal of Psychiatry and Neuroscience, 2008, 33, 516-24.	2.4	62
246	Anxiety Comorbidity and Quality of Life in Bipolar Disorder Patients. Canadian Journal of Psychiatry, 2007, 52, 175-181.	1.9	67
247	Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behavioural Pharmacology, 2007, 18, 205-212.	1.7	45
248	The role of hippocampus in the pathophysiology of bipolar disorder. Behavioural Pharmacology, 2007, 18, 419-430.	1.7	149
249	Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. NeuroReport, 2007, 18, 1567-1570.	1.2	24
250	DNA damage in bipolar disorder. Psychiatry Research, 2007, 153, 27-32.	3.3	145
251	Manic symptoms and quality of life in bipolar disorder. Psychiatry Research, 2007, 153, 33-38.	3.3	35
252	Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 283-285.	4.8	104

#	Article	IF	CITATIONS
253	DNA damage in rats after treatment with methylphenidate. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1282-1288.	4.8	64
254	Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neuroscience Letters, 2007, 415, 87-89.	2.1	58
255	Fluvoxamina no transtorno depressivo maior: um estudo multic \tilde{A}^a ntrico aberto. Jornal Brasileiro De Psiquiatria, 2007, 56, 17-22.	0.7	1
256	Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Molecular Psychiatry, 2007, 12, 230-231.	7.9	51
257	Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo1H MRS study. Bipolar Disorders, 2007, 9, 119-127.	1.9	107
258	Mismatch between self-reported quality of life and functional assessment in acute mania: A matter of unawareness of illness?. Journal of Affective Disorders, 2007, 103, 247-252.	4.1	49
259	Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences, 2006, 79, 281-286.	4.3	211
260	Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters, 2006, 398, 215-219.	2.1	343
261	Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neuroscience Letters, 2006, 407, 146-150.	2.1	84
262	Glial fibrillary acidic protein expression after electroconvulsive shocks in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 663-667.	4.8	6
263	Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1231-1234.	4.8	15
264	Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behavioural Pharmacology, 2006, 17, 311-318.	1.7	41
265	Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disorders, 2006, 8, 275-280.	1.9	95
266	Changes in Antioxidant Defense Enzymes after d-amphetamine Exposure: Implications as an Animal Model of Mania. Neurochemical Research, 2006, 31, 699-703.	3.3	90
267	Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Research, 2006, 1097, 224-229.	2.2	75
268	Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience, 2006, 31, 326-32.	2.4	176
269	A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Human Psychopharmacology, 2005, 20, 133-139.	1.5	24
270	The role of depression in coronary artery disease. Arquivos Brasileiros De Cardiologia, 1999, 73, 237-250.	0.8	1

BenÃcio N Frey

#	Article	IF	CITATIONS
271	Lifestyle Behaviors, Depression, and Anxiety Among Individuals Living in Canada During the COVID-19 Pandemic. American Journal of Lifestyle Medicine, 0, , 155982762211020.	1.9	O